Skip to main content
Premium Trial:

Request an Annual Quote

Bio Report, Part I: Drug Discovery Collins: NIH Chemical Genomics Effort Would Be Timely

Premium

With a nod to Star Trek, Francis Collins’ speech at the annual BIO conference, “Genome Research, The Next Generation,” gave credence to NHGRI’s journey into uncharted territory. Beyond reiterating the institute’s published goals for the future, as laid out in an April paper published in Nature, Collins emphasized getting NHGRI — and NIH as a whole — to participate more actively in early-stage drug discovery through a planned NIH-wide chemical genomics intiative.

The details of the initiative are still in flux, but Collins told the audience assembled at BIO that a public-sector initiative in chemical genomics “would be timely,” given the rapid development of resources and technologies such as combinatorial chemistry, extensive compound libraries, and robotic screening — not to mention the Human Genome Project itself.

“Am I suggesting that all NIH researchers become drug developers? No,” he said. But he added that the institute could play a significant role in developing assays to screen for potential drug-like compounds, and at the very least use small molecule compounds as reagents in experiments designed to investigate disease mechanisms. “From a public science perspective, instead of siRNAs, we could use chemical probes [to study biological pathways],” he said.

Collins said NIH Director Elias Zerhouni shares his desire to see public-sector science play a larger role in early-stage research that could lead to new drugs. And to do so, he admitted that the institutes would have to file for intellectual property rights to preserve the possibility of licensing compounds to commercial drug developers. “With small molecule efforts, we’d have to capture the IP early on, or else we’d have a lot of molecules that no one [in pharma] wants to touch,” he said.

The development came out of the NIH-wide road-mapping exercise, Collins told GT, adding that he expected more concrete announcements regarding the initiative “in the next month or so,” following BIO’s meeting in early June. “We at the genome institute are extremely interested in helping move that forward,” he said.

— John S. MacNeil

 

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.